DRI Healthcare Trust (TSE:DHT.UN – Free Report) had its target price trimmed by National Bankshares from C$19.50 to C$17.50 in a research report report published on Thursday morning,BayStreet.CA reports. The firm currently has an outperform rating on the stock.
DHT.UN has been the subject of a number of other research reports. CIBC cut their price target on shares of DRI Healthcare Trust from C$19.50 to C$18.00 and set an “outperform” rating for the company in a report on Thursday, December 12th. Raymond James lowered their price objective on shares of DRI Healthcare Trust from C$23.00 to C$22.00 in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, DRI Healthcare Trust presently has a consensus rating of “Moderate Buy” and a consensus target price of C$17.94.
Check Out Our Latest Stock Report on DRI Healthcare Trust
DRI Healthcare Trust Stock Down 0.2 %
About DRI Healthcare Trust
DRI Healthcare Trust is an open-ended trust that provides unitholders with differentiated exposure to the anticipated growth in the global pharmaceuticals and biotechnology markets. Its business model is focused on managing and growing a diversified portfolio of pharmaceutical royalties to deliver attractive growth in cash royalty receipts over the long term.
See Also
- Five stocks we like better than DRI Healthcare Trust
- 3 Monster Growth Stocks to Buy Now
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- How to Capture the Benefits of Dividend Increases
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Canadian Penny Stocks: Can They Make You Rich?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for DRI Healthcare Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DRI Healthcare Trust and related companies with MarketBeat.com's FREE daily email newsletter.